TREAT-MS: design and baseline characteristics of a noninterventional study to establish effectiveness, quality of life, cognition, health-related, and work capacity data on alemtuzumab in multiple sclerosis patients in Germany
Author(s): ,
T. Ziemssen
Affiliations:
Center of Clinical Neuroscience, Carl Gustav Carus University Hospital, Dresden
,
A. Leptich
Affiliations:
Clinical Study Unit, Sanofi-Aventis Deutschland GmbH, Frankfurt am Main
,
S. Jahn
Affiliations:
Medical Affairs, Genzyme GmbH, Neu-Isenburg, Germany
,
R. Kern
Affiliations:
Center of Clinical Neuroscience, Carl Gustav Carus University Hospital, Dresden
,
U. Engelmann
Affiliations:
Medical Affairs, Genzyme GmbH, Neu-Isenburg, Germany
on behalf of the TREAT-MS Study Group
on behalf of the TREAT-MS Study Group
Affiliations:
ECTRIMS Online Library. Ziemssen T. Oct 9, 2015; 115890; 1292
Dr. Tjalf Ziemssen
Dr. Tjalf Ziemssen
Contributions
Abstract
Abstract: P1145

Type: Poster

Abstract Category: Others

Background: Alemtuzumab, a humanised monoclonal antibody, is licensed in Germany since October 2013 as treatment for patients with active relapsing-remitting multiple sclerosis (RRMS). In 2-year phase 3 studies, alemtuzumab had superior efficacy as compared to subcutaneous interferon beta-1a and durable efficacy over 4 years in an extension study with manageable safety in RRMS patients.

Goals: To report on the study design and baseline characteristics of enrolled patients in TREAT-MS: a non-interventional long-Term study foR obsErvAtion of Treatment with LEMTRADA® in active RRMS.

Methods: This noninterventional effectiveness study is a prospective treatment with alemtuzumab in approximately 3000 RRMS patients from neurological clinics and practices. Planned recruitment is until end of 2016. The study comprises a 5-year observation period. The following instruments will be used: Patient-Reported Outcome Indices for Multiple Sclerosis (PRIMUS), EuroQoL EQ-5D™, Work Productivity and Activity Impairment (WPAI), and Symbol Digit Modalities Test (SDMT). The Multiple Sclerosis Documentation System (MSDS) Project Development Group in Dresden adapted the patient-management software, MSDS3D, for use in this study. TREAT-MS will also fulfil a quality assurance function. Risk-management plan (RMP) measures such as monitoring for thyroid disorders, immune thrombocytopenia and nephropathies, and regular laboratory tests/urinalyses are represented in TREAT-MS and integrated into MSDS3D.

Results: Study enrolment began in October 2014 and 80 patients have been enrolled to date. First baseline characteristic data will be presented.

Conclusion: Implementation of RMP and perspective documentation of efficacy/safety data are combined in the TREAT-MS study.

Disclosure: Study supported by Genzyme, a Sanofi company.

TZ: Compensation for consulting services (Almirall, Bayer, Biogen Idec, Genzyme, GlaxoSmithKline, MSD, Merck Serono, Novartis, Sanofi, Synthon, and Teva); financial support for research activities (Bayer, Biogen Idec, Merck Serono, Novartis, Sanofi, and Teva).

AL:
Compensation as an employee (Sanofi Aventis).

SJ: Compensation as an employee (Genzyme).

RK: Compensation for consulting services (Teva, Bayer Healthcare, Genzyme, Biogen Idec, and Novartis).

UE:
Compensation as an employee (Genzyme).

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies